Lexicon Pharmaceuticals | LXRX - Capital Ordinário





Capital Ordinário Alterar Data
Abbott USD 1.74B 23.39B 2025-09
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Agios Pharmaceuticals USD 58.45M 169K 2025-12
Akebia Therapeutics USD 265.42M 199K 2025-12
Alnylam Pharmaceuticals USD 132.38M 585K 2025-12
AstraZeneca USD 1.55B 206K 2025-12
BioMarin Pharmaceutical USD 192.3M 201K 2025-12
Coherus Biosciences USD 121.16M 4.92M 2025-12
Eli Lilly USD 946.83M 354.23M 2025-06
Esperion Therapeutics USD 245.22M 39.79M 2025-12
Halozyme Therapeutics USD 117.78M 259K 2025-12
Illumina USD 152.8M 900K 2025-12
Insmed USD 214.26M 1.67M 2025-12
Ironwood Pharmaceuticals USD 160K 0 2024-12
J&J USD 2.41B 584K 2025-09
Lexicon Pharmaceuticals USD 363.47M 67K 2025-12
MacroGenics USD 63.32M 60K 2025-12
MannKind USD 307.83M 806K 2025-12
Merck USD 2.49B 15.79M 2025-09
Moderna USD 391M 2M 2025-09
Novartis USD 1.91B 10.64M 2025-12
PTC Therapeutics USD 81.47M 1.54M 2025-12
Puma Biotechnology USD 5K 0 2024-06
Sarepta Therapeutics USD 104.96M 196K 2025-12
Thermo Fisher Scientific USD 375.71M 1.9M 2025-12
Ultragenyx Pharmaceutical USD 96.44M 88K 2025-09
United Therapeutics USD 43.64M 740K 2025-12
Vanda Pharmaceuticals USD 58K 0 2024-12